Cefprozil is a second-generation cephalosporin antibiotic with broad-spectrum antibacterial activity. It is indicated for the treatment of mild to moderate infections caused by susceptible bacteria, including:
- Upper respiratory tract infections:
- Streptococcus pyogenes pharyngitis/tonsillitis;
- Otitis media and acute sinusitis caused by Streptococcus pneumoniae, Haemophilus influenzae (including β-lactamase–producing strains), and Moraxella catarrhalis (including β-lactamase–producing strains).
- Lower respiratory tract infections:
- Acute bacterial exacerbations of chronic bronchitis and acute bacterial bronchitis caused by S. pneumoniae, H. influenzae (including β-lactamase–producing strains), and M. catarrhalis (including β-lactamase–producing strains).
- Skin and skin structure infections:
- Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains) and Streptococcus pyogenes (note: abscesses usually require surgical drainage).
Cefprozil is the first oral cephalosporin approved by the U.S. FDA for the treatment of otitis media and sinusitis in children. It demonstrates potent activity against β-lactamase–producing strains of S. aureus, H. influenzae, and M. catarrhalis, making it suitable for treating infections caused by these resistant organisms. Among oral second-generation cephalosporins, cefprozil exhibits favorable activity against S. pneumoniae and is recommended by the Infectious Diseases Society of America (IDSA) for the treatment of community-acquired pneumonia caused by penicillin-susceptible S. pneumoniae, although this indication has not yet received FDA approval.